Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QTP101
- Development stage
- Unknown
- Lead developer
- Quratis
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**QTP101** is an investigational intramuscular tuberculosis vaccine developed by Quratis from the ID93+GLA-SE platform. It is a recombinant protein-subunit vaccine containing the four *Mycobacterium tuberculosis* antigens Rv1813, Rv2608, Rv3619, and Rv3620 fused as ID93, formulated with the glucopyranosyl lipid A stable-emulsion adjuvant GLA-SE. GLA is a Toll-like receptor 4 agonist intended to enhance antigen-specific cellular and humoral immunity, including T-helper 1-biased responses. QTP101 is being developed as a Bacillus Calmette-Guérin booster vaccine to prevent tuberculosis disease, including in adolescents, adults, and older adults. Quratis-sponsored studies have evaluated the candidate in BCG-vaccinated populations, while the broader ID93+GLA-SE program has reached Phase 2 clinical development. ([quratis.com](https://www.quratis.com/m2/business/business01.php))
- Other names
- ID93 + GLA-SEID93+GLA-SEID93/GLA-SE
02
Targets
BCR-ID93 (B-cell receptor recognizing ID93 epitopes)TCR-ID93 (T-cell receptor recognizing ID93-derived peptides)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on QTP101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QTP101.